Riskpilot← Back to searchSign inGet full accessINAGEN ApS
APSIn liquidationCVR 30721632Kongevejen 371Forskning og eksperimentel udvikling indenfor bioteknologi · NACE 721100Est. 2007— employees
Revenue 2014
DKK 54K
-130% vs 2013
EBITDA margin
100.0%
+130% vs 2013
Equity ratio
-4716.6%
Financial strength
Net profit 2014
DKK -1,1M
+23% vs 2013
| Revenue | DKK 54K | -130% |
| EBITDA | DKK 54K | +130% |
| Net profit | DKK -1,1M | +23% |
| Total assets | DKK 257K | +25% |
| Equity | DKK -12,1M | -10% |
| Employees | — | — |
Legal name
INAGEN ApS
CVR number
30721632
Legal form
Anpartsselskab
NACE code
721100 · Forskning og eksperimentel udvikling indenfor bioteknologi
Founded
7. juli 2007
Share capital
DKK 508.599
Employees
—
VAT registered
No
Audit selected
No
Last report
2014-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Kongevejen 371
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 |
|---|---|---|---|
| Revenue | -764 | -179 | 54 |
| Staff expenses | -635 | -0 | -0 |
| EBITDA | -1.457 | -179 | 54 |
| Depreciation & amort. | -0 | -0 | -0 |
| EBIT | -1.457 | -179 | 54 |
| Net financials | -1.205 | -1.206 | -1.209 |
| Profit before tax | -2.662 | -1.385 | -1.155 |
| Tax | -0 | -0 | -84 |
| Net profit | -2.662 | -1.385 | -1.071 |
| Item | 2012 | 2013 | 2014 |
|---|---|---|---|
| Total assets | 447 | 206 | 257 |
| Equity | — | -11.074 | -12.145 |
| Long-term debt | 9.972 | 11.172 | 12.372 |
| Short-term debt | 163 | 108 | 30 |
| Total debt | 10.135 | 11.280 | 12.402 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20122014
Equity ratio
-4716.6%
This company
38.2%
Market median
-12447% vs market
20122014
Return on equity
-107054600.0%
This company
18.4%
Market median
-581818578% vs market
20122014
Net profit margin
-1970.3%
This company
8.1%
Market median
-24425% vs market
20122014
Asset turnover
0.21×
This company
1.12×
Market median
-81% vs market
20122014
Debt / equity
1.02×
This company
0.62×
Market median
-65% vs market
20122014
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TN Chief Executive Officer | Chief Executive Officer | 2008 | — | — |
JB Unofficial title | Unofficial title | 2015 | — | — |
MM Founder | Founder | 2007 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2007 | — | — | |
| Board of Directors | 2007 | — | — | |
| Board of Directors | 2008 | — | — | |
| Chairman | 2012 | — | — | |
| Board of Directors | 2007 | — | — | |
| Chairman | 2008 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
TNK BIOTECH ApS | Company | 10.0% | 10.0% | 2007 |
Novo Holdings A/S | Company | 50.0% | 50.0% | 2009 |
CAT SEED A/S | Company | 20.0% | 20.0% | 2009 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of INAGEN ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Nitschke Kledal | Chief Executive Officer | 0 companies |
| Jan Bjerrum Bach | Unofficial title | 0 companies |
| Mette Marie Rosenkilde | Founder | 0 companies |
| Jørgen Søberg Petersen | Board of Directors | 0 companies |
| Sean Arthur Macdonald | Board of Directors | 0 companies |
| Leif Helth Jensen | Board of Directors | 0 companies |
| Stephan Christgau | Chairman | 0 companies |
| Christian Ellebæk Elling | Board of Directors | 0 companies |
| Peter Samuel Wulff | Chairman | 0 companies |